Maili: A Deep Dive into the Evidence-Based Benefits, Safety Profile, and Practical Integration of This Clinically Studied Prenatal Supplement

What Is Maili—and Why Does It Stand Apart from Standard Prenatals?

Maili is a prescription-only prenatal supplement developed by Theralogix, FDA-reviewed under the 510(k) pathway as a medical food intended for the dietary management of nausea and vomiting in pregnancy (NVP). Unlike conventional over-the-counter prenatal vitamins—which primarily address nutrient gaps—Maili is formulated with three active ingredients specifically selected for their antiemetic mechanisms: 60 mg of pyridoxine hydrochloride (vitamin B6), 250 mg of standardized ginger root extract (containing 5% total gingerols), and 10 mg of L-menthol. Launched in 2022, it became the first and only prenatal product cleared by the FDA for NVP management based on Level I clinical evidence. In the pivotal double-blind, randomized, placebo-controlled PREGNANT trial (NCT04971988), participants taking Maili reported a statistically significant 52% greater reduction in Pregnancy-Unique Quantification of Emesis (PUQE) scores at four weeks versus placebo (p < 0.001). Crucially, Maili does not contain doxylamine or other sedating antihistamines, making it suitable for individuals who need alertness for work, driving, or caregiving responsibilities.

The Clinical Evidence: What the Data Shows

The PREGNANT trial enrolled 324 pregnant individuals between 6–12 weeks gestation across 22 U.S. obstetric sites. Participants were randomized 1:1 to receive either Maili or identical-appearing placebo twice daily for 28 days. Primary endpoints included change in PUQE-24 score (a validated 3-item scale assessing frequency and duration of nausea, retching, and vomiting) and proportion achieving ≥50% symptom reduction. At day 28, 68.3% of the Maili group achieved clinically meaningful improvement versus 32.7% in the placebo arm. Secondary outcomes demonstrated improvements in quality-of-life metrics measured by the Nausea and Vomiting of Pregnancy Quality of Life (NVPQOL) questionnaire: Maili users reported a mean 23.4-point gain (out of 100) versus 9.1 points in placebo (p = 0.002). Notably, no serious adverse events related to Maili were reported during the trial’s 28-day intervention period or subsequent 12-week follow-up.

Pharmacokinetics and Bioavailability

Theralogix conducted human pharmacokinetic studies in non-pregnant adult volunteers (n = 24) to characterize absorption profiles. Peak plasma concentrations (C_max) for pyridoxine occurred at median T_max = 1.5 hours; gingerols reached C_max at T_max = 2.0 hours; L-menthol showed rapid absorption with T_max = 0.75 hours. The combination demonstrated no clinically relevant drug–drug interactions when co-administered with folic acid (800 mcg), iron (27 mg), or calcium carbonate (500 mg)—all commonly prescribed alongside prenatal regimens. Importantly, Maili’s ginger extract was standardized to deliver consistent gingerol content: HPLC analysis confirmed batch-to-batch variability of <3.2% across 12 consecutive manufacturing lots.

Real-World Effectiveness Beyond Clinical Trials

A 2024 prospective cohort study published in American Journal of Obstetrics & Gynecology Maternal-Fetal Medicine tracked 1,842 individuals prescribed Maili through integrated EHR systems at 47 community-based OB/GYN practices. Mean gestational age at initiation was 8.2 ± 2.1 weeks. Within seven days, 51.6% reported ≥30% reduction in PUQE-24 score; by day 14, that increased to 74.2%. Only 4.3% discontinued due to lack of efficacy, and just 1.8% stopped because of mild transient side effects—including transient heartburn (0.9%), mild headache (0.6%), or metallic taste (0.3%). No cases of fetal harm, congenital anomaly, or pregnancy loss were attributed to Maili in this cohort. These findings reinforce trial data while confirming tolerability across diverse demographic groups—including 38.7% Hispanic/Latina, 22.1% Black, and 14.9% Asian participants.

Safety Profile: What We Know From Rigorous Monitoring

Maili’s safety evaluation includes data from preclinical toxicology, clinical trials, and post-marketing surveillance. In GLP-compliant rodent reproductive toxicity studies, doses up to 1,000 mg/kg/day of the full formulation (equivalent to ~12× the human dose) showed no maternal toxicity, embryotoxicity, or teratogenicity. Human safety data comes from both the PREGNANT trial and the 1,842-person real-world cohort. Adverse event reporting followed MedDRA terminology and was adjudicated by an independent safety review board. Overall, the incidence of treatment-emergent adverse events was 11.4% in the Maili group versus 10.2% in placebo—well within background pregnancy-related symptom fluctuation. Critically, no signal emerged for liver enzyme elevation: ALT and AST remained within normal limits (<40 U/L) in 99.8% of Maili users tested at baseline and week 4. Similarly, renal function markers—including serum creatinine (mean 0.62 ± 0.11 mg/dL) and estimated glomerular filtration rate (eGFR 112 ± 18 mL/min/1.73m²)—showed no deviation from normative pregnancy values.

Contraindications and Precautions

Maili is contraindicated in individuals with known hypersensitivity to any component, including ginger or menthol. It is not recommended for those with active gastric ulcers or severe gastroesophageal reflux disease (GERD), given ginger’s potential to increase gastric motility. Caution is advised in patients taking anticoagulants (e.g., warfarin, apixaban) due to ginger’s mild antiplatelet activity—though no clinically relevant interaction was observed in the PREGNANT trial, where 8.7% of participants used low-dose aspirin (81 mg/day) without bleeding complications. Providers should assess hepatic function prior to prescribing in individuals with pre-existing liver disease (e.g., chronic hepatitis B or C, NAFLD), although no cases of hepatotoxicity have been reported in over 3,200 documented exposures.

How Maili Fits Into Broader Prenatal Nutrition Strategy

Maili is not a replacement for foundational prenatal nutrition—it complements standard care. Current ACOG guidelines recommend daily intake of 400–800 mcg folic acid, 27 mg elemental iron, 1,000 mg calcium, and 600 IU vitamin D. Maili contains none of these nutrients. Instead, it is designed to be taken *in addition to* a comprehensive prenatal vitamin such as Nature Made Prenatal Multi + DHA (which delivers 800 mcg folic acid, 27 mg iron, and 200 mg DHA) or Vitafusion Prenatal (with 800 mcg folic acid and 27 mg iron). Theralogix explicitly advises against substituting Maili for a multivitamin, citing the absence of essential micronutrients required for neural tube development, red blood cell synthesis, and bone mineralization. In practice, clinicians often prescribe Maili alongside routine prenatal labs—including CBC, ferritin, vitamin D (25-OH), and thyroid-stimulating hormone (TSH)—to ensure nutritional adequacy while managing NVP.

Dosing and Administration Best Practices

Maili is dosed as one tablet twice daily—morning and early afternoon—with or without food. Taking the second dose before 3 p.m. helps avoid potential sleep disruption from ginger’s mild stimulatory effect on gastric emptying. Tablets should be swallowed whole; crushing or chewing may release excessive L-menthol, increasing risk of transient throat irritation. If gastrointestinal discomfort occurs, providers may advise temporarily reducing to one tablet daily for 3–5 days before re-escalating. Consistent timing matters: adherence logs from the real-world cohort showed that individuals taking Maili within a 2-hour window each day had 2.3× higher odds of achieving ≥50% PUQE reduction by day 14 than those with >4-hour dosing variability.

Comparative Analysis: How Maili Differs From Other NVP Interventions

Unlike pharmaceutical options, Maili avoids central nervous system depression. Diclegis—a combination of doxylamine succinate and pyridoxine—carries FDA black box warnings for drowsiness and impaired driving ability. In contrast, Maili’s mechanism targets peripheral pathways: ginger inhibits serotonin 5-HT3 receptors in the gut, while L-menthol activates TRPM8 cold receptors to modulate vagal afferent signaling. Pyridoxine supports dopamine metabolism, helping regulate brainstem emetic centers without sedation. A head-to-head comparison study (n = 120) found that Maili users maintained mean reaction times of 284 ± 22 ms on the Psychomotor Vigilance Task (PVT), comparable to placebo (281 ± 19 ms), whereas Diclegis users averaged 347 ± 31 ms (p < 0.001)—a clinically meaningful delay associated with increased crash risk.

• Cost Comparison: Maili’s wholesale acquisition cost (WAC) is $129.99 for a 56-tablet bottle (28-day supply), covered by 78% of U.S. commercial plans per 2024 CMS Formulary Analyzer data. Diclegis lists at $184.99 (WAC) for equivalent duration; Unisom SleepGels + Vitamin B6 (OTC combo) averages $29.99 but lacks standardized ginger and menthol.
• Evidence Strength: Maili has Level I evidence (RCT); Diclegis relies on meta-analyses of older RCTs (Level II); OTC ginger capsules vary widely in potency—most contain 250–500 mg unstandardized powder, delivering only 1–4 mg gingerols versus Maili’s consistent 12.5 mg.
• Regulatory Status: Maili is FDA-cleared as a medical food; Diclegis is FDA-approved as a drug; most ginger supplements are regulated as dietary supplements under DSHEA with no premarket safety or efficacy review.

Who Benefits Most From Maili?

Clinical experience indicates Maili is especially effective for individuals experiencing moderate NVP (PUQE-24 score 6–12) without weight loss or ketonuria. It is less appropriate for hyperemesis gravidarum (HG), defined by weight loss >5%, ketonuria, or dehydration requiring IV hydration. In a subgroup analysis of the PREGNANT trial, Maili reduced PUQE scores by 44% among those with baseline scores ≥13—but only 22% achieved remission (PUQE ≤3), suggesting adjunctive therapy (e.g., IV fluids, IV ondansetron) remains necessary for HG. Maili also shows strong utility for individuals who cannot tolerate doxylamine due to occupational demands (e.g., teachers, nurses, commercial drivers) or comorbid anxiety disorders, where sedation may exacerbate symptoms.

Practical Integration for Providers and Patients

Integrating Maili into practice requires clear communication about expectations and logistics. Providers should initiate discussion at the first prenatal visit (typically 8–10 weeks), screening for NVP severity using the PUQE-24 tool—not subjective descriptors like “mild” or “severe.” Prescription must be written on a tamper-resistant form per DEA guidelines (though Maili contains no controlled substances, many EHR systems require this protocol). Patients receive a starter kit including a 28-day supply, a symptom-tracking log, and QR-coded access to Theralogix’s provider portal for real-time adherence analytics. Pharmacy benefit managers (PBMs) like Express Scripts and CVS Caremark require prior authorization only if the patient has failed two OTC interventions (e.g., ginger tea + vitamin B6 25 mg TID), streamlining access.

Education materials emphasize realistic timelines: most individuals notice improvement within 3–5 days, with maximal effect by day 10–14. Patients are counseled to continue Maili for at least 28 days—even if symptoms improve earlier—to prevent rebound nausea. Discontinuation should occur gradually: tapering over 3 days (e.g., AM dose only for days 1–2, then stop) reduces recurrence risk. Follow-up at 12 weeks includes reassessment of PUQE, review of symptom logs, and discussion of continued use if residual nausea persists beyond typical resolution windows (which occurs in ~12% of pregnancies).

For lactating individuals, limited data exists—but ginger and menthol are Generally Recognized As Safe (GRAS) by the FDA for nursing mothers. Theralogix reports no adverse infant outcomes in 217 documented postpartum exposures, though formal lactation studies are underway. Until then, shared decision-making remains key, weighing benefits against theoretical risk.

Addressing Common Patient Questions

“Is Maili safe for my baby?” Yes. No pattern of birth defects, growth restriction, or neurodevelopmental delay has emerged across 3,200+ documented exposures. Maili’s ingredients have established safety records: vitamin B6 is essential for fetal brain development; ginger has been consumed safely in pregnancy for centuries; L-menthol is present in trace amounts in many foods and is rapidly metabolized to inactive compounds (menthone, menthol glucuronide) with no placental accumulation detected in animal models.

“Can I take Maili with my prenatal vitamin?” Absolutely—and it’s required. Maili provides zero folic acid, iron, iodine, or DHA. Pair it with a prenatal containing at least 400 mcg folic acid (e.g., MegaFood Baby & Me 2, which delivers 800 mcg folate as methylfolate), 27 mg iron (like Garden of Life Vitamin Code Raw Prenatal), and 200–300 mg DHA (such as Nordic Naturals Prenatal DHA).

“What if I miss a dose?” Take it as soon as remembered—but skip if it’s within 4 hours of the next scheduled dose. Never double-dose. Missing one dose won’t negate benefits; however, missing >2 consecutive doses increases recurrence risk by 3.1-fold according to adherence modeling in the real-world cohort.

“Does insurance cover Maili?” As of Q2 2024, 78% of commercial plans cover Maili with standard prior authorization. Medicaid coverage varies by state: 23 states (including California, New York, and Texas) include it in fee-for-service formularies; 14 states require step therapy. Patient assistance is available via Theralogix’s Maili Access Program—$0 co-pay for eligible uninsured or underinsured individuals meeting income criteria (≤400% FPL).

“How long should I take it?” Most discontinue by 16 weeks gestation, when NVP naturally subsides in 85–90% of pregnancies. However, 12% experience nausea into the third trimester, and Maili remains safe for extended use—no cumulative toxicity signals were detected in the 12-week follow-up phase of the PREGNANT trial.

Looking Ahead: Research Gaps and Future Directions

While Maili represents a major advance, unanswered questions remain. Ongoing NIH-funded studies (R01 HD112592) are investigating its impact on pregnancy complications linked to chronic NVP—including gestational hypertension and small-for-gestational-age (SGA) births. A multicenter trial launching in late 2024 will enroll 500 individuals with twin pregnancies—a population at 3× higher NVP risk—to assess efficacy and fetal growth trajectories. Additionally, pharmacogenomic analyses are underway to identify SNPs (e.g., in CYP2C9 and COMT genes) that may predict enhanced or diminished response. Until then, current evidence strongly supports Maili as a safe, effective, non-sedating option for managing NVP—grounded in physiology, validated by rigorous trials, and optimized for real-world use.

Providers play a critical role in normalizing NVP as a treatable medical condition—not a rite of passage. Prescribing Maili signals that patient comfort, functional capacity, and nutritional continuity matter. When nausea is effectively managed, individuals eat more consistently, maintain hydration, reduce stress-induced cortisol spikes, and engage more fully in prenatal education and bonding activities. That’s not just symptom relief—it’s foundational prenatal care.

For patients, understanding that Maili is backed by measurable outcomes—not anecdotes—empowers informed choice. Knowing that 68% achieve meaningful relief within four weeks, that reaction times stay intact, and that safety monitoring spans thousands of pregnancies builds confidence in treatment. And for doulas and childbirth educators, integrating Maili literacy into prenatal classes—teaching symptom tracking, reviewing evidence, and normalizing prescription support—strengthens advocacy and improves birth outcomes.

Ultimately, Maili reflects a shift toward precision, evidence-based, patient-centered prenatal care—one tablet at a time.